08:14 AM EDT, 08/01/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q2 adjusted earnings Thursday of $1.63 per diluted share, up from $1.25 a year earlier.

Analysts polled by Capital IQ expected $1.53.

Revenue for the quarter ended June 30 was $590.2 million, up from $452.7 million a year earlier.

Analysts polled by Capital IQ expected $546.5 million.

The company said it ended Q2 with $1.68 billion in cash, cash equivalents, and marketable securities.

Shares of the company were up 6% in recent Thursday premarket activity.

Price: 147.92, Change: +6.35, Percent Change: +4.49